Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Translational research

4205 - A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1


09 Sep 2017


Translational research


Roger Sun


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


R. Sun1, E.J. Limkin2, L. Dercle3, S. Champiat4, S. Reuzé2, D. Brandao5, L. Verlingue4, S. Ammari6, S. Aspeslagh7, A. Schernberg1, S. Postel-Vinay8, A. Hollebecque4, C. Massard7, A. Marabelle7, C. Robert2, J. Soria8, E. Deutsch1, C. Ferté9

Author affiliations

  • 1 Radiotherapy Department, Radiomics Inserm U1030, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Radiomics Inserm U1030, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Nuclear Medicine, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Drug Development Department (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Inserm U1170, Gustave Roussy Cancer Campus Grand Paris, 94800 - Villejuif/FR
  • 6 Radiology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 7 Drug Development Department (ditep), Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 8 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 9 Head And Neck, Gustave Roussy, 94805 - Villejuif/FR


Abstract 4205


Tumor infiltrating lymphocytes (TIL) appears necessary to trigger anticancer activity of anti-PD-1/PD-L1. Radiomics consists in the analysis of quantitative data extracted from standard medical imaging to generate imaging biomarkers. We developed a radiomics-based predictor of TIL and investigated whether such signature could predict the outcome of patients treated by anti-PD1/PD-L1.


We first developed a predictive model of tumor infiltrating CD8 T cells with RNA-Seq and raw imaging data (CT –Scan) using random forest in 69 HNSCC patients from the TCGA (The Cancer Genome Atlas)/TCIA (The Cancer Imaging Archive) database. CD8 T cells were estimated by the Microenvironment Cell Populations-counter signature. To validate our tool, this signature was applied to a first independent cohort of 100 patients for which the pathologic TIL was assumed as either high (lymphoma, melanoma, lung, bladder, renal and MSI+ cancers; 30 patients) or low (adenoid cystic carcinoma, low-grade neuroendocrine tumors, uterine leiomyoma; 70 patients). Finally, we applied our signature on a second cohort of 139 patients prospectively enrolled in anti-PD-1/PD-L1 phase 1 trials to infer its relation with patient outcome (Overall Survival).


We developed a CD8 radiomics-based signature with six out of the 80 extracted features from CT-scans. As an internal validation, the correlation of this signature with the estimated TCGA CD8 was: spearman’s rho=0.81 (P 


The radiomics-based signature of TIL was validated in two external cohorts. It appears a promising tool to estimate TIL and to infer the outcome of metastatic patients treated with anti-PD1/PD-L1.

Clinical trial identification

Legal entity responsible for the study

Ferté Charles




L. Verlingue: consulting Adaptherapy J-C. Soria: Consultancy fees from AstraZeneca, Astex, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pharmamar Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.